PTAFR and ovarian carcinoma: As we previously reported that inhibition of PAFR decrased ovarian cancer cell proliferation and the EGFR inhibition has shown promise in clinical trials in various types of cancers, including ovarian cancer, we asked whether simultaneously targeting the two receptors would have synergistic effects.